ReviewPharmaceuticals (Basel, Switzerland)2020
Role of Chronic Lymphocytic Leukemia (CLL)-Derived Exosomes in Tumor Progression and Survival.
Review in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 31 citations in OpenAlex.
- Diagnosis, prognostic prediction of the accelerated phase of chronic lymphocytic leukaemia: a narrative review.Contemporary oncology (Poznan, Poland) · 2026Review
- Harnessing the power of exosomes in leukemia: from molecular messengers to clinical applications.Discover oncology · 2025Review
- Navigating the Landscape of Exosomal microRNAs: Charting Their Pivotal Role as Biomarkers in Hematological Malignancies.Non-coding RNA · 2025Review
- TGF-β-Enriched Exosomes from Acute Myeloid Leukemia Activate Smad2/3-MMP2 and ERK1/2 Signaling to Promote Leukemic Cell Proliferation, Migration, and Immune Modulation.Current issues in molecular biology · 2025Article
- CD20-bearing extracellular vesicles are associated with prognostic biomarkers of patients with AIDS-NHL.Scientific reports · 2025Article
- Innovative Applications of Nanopore Technology in Tumor Screening: An Exosome-Centric Approach.Biosensors · 2025Review
- Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.Stem cell research & therapy · 2025Review
- The theragnostic advances of exosomes in managing leukaemia.Journal of cellular and molecular medicine · 2024Review
- Plasma-derived exosomal miR-326, a prognostic biomarker and novel candidate for treatment of drug resistant pediatric acute lymphoblastic leukemia.Scientific reports · 2024Article
- The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia.Cancers · 2023Review
- Understanding of Ovarian Cancer Cell-Derived Exosome Tropism for Future Therapeutic Applications.International journal of molecular sciences · 2023Article
- Review
- Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently.Science China. Life sciences · 2023Article
- Article
- Multiple functions and regulatory network of miR-150 in B lymphocyte-related diseases.Frontiers in oncology · 2023Review
- Exosome application in treatment and diagnosis of B-cell disorders: leukemias, multiple sclerosis, and arthritis rheumatoid.Cellular & molecular biology letters · 2022Review
- Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications.Biomarker research · 2022Review
- Targeted Drug Delivery for Chronic Lymphocytic Leukemia.Pharmaceutical research · 2022Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Chronic lymphocytic leukemia (CLL) is a B-lymphoproliferative disease, which consists of the abnormal proliferation of CD19/CD5/CD20/CD23 positive lymphocytes in blood and lymphoid organs, such as bone marrow, lymph nodes and spleen. The neoplastic transformation and expansion of tumor B cells are commonly recognized as antigen-driven processes, mediated by the interaction of antigens with the B cell receptor (BCR) expressed on the surface of B-lymphocytes. The survival and progression of CLL cells largely depend on the direct interaction of CLL cells with receptors of accessory cells of tumor microenvironment. Recently, much interest has been focused on the role of tumor release of small extracellular vesicles (EVs), named exosomes, which incorporate a wide range of biologically active molecules, particularly microRNAs and proteins, which sustain the tumor growth. Here, we will review the role of CLL-derived exosomes as diagnostic and prognostic biomarkers of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.